Equibles does not estimate personal net worth.
InspireMD, Inc. reported in an 8-K filed July 29, 2026 that Shane Gleason was terminated as Chief Commercial Officer, effective July 31, 2026. The proxy statement of InspireMD, Inc. reports total compensation of $1,108,199 for Shane Gleason in fiscal 2023, including a base salary of $274,275. Disclosed compensation is on record for 2 fiscal years. Shane Gleason has spoken on 1 earnings call across 1 company, most recently for InspireMD, Inc. on May 4, 2026. The companies whose calls Shane Gleason spoke on are classified in the Healthcare sector.
“On July 23, 2026, InspireMD, Inc. (the “Company”) provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated.”
“I think the short answer is this is one of those where all politics is local applies, but that's something that our team in the field is staying close to and you're exactly right in a lot of those cases what they what they really approved is the stent and you can probably imagine that the team has been out there…”
Proxy statement
Start not stated–2026-07-31
NSPR
Medical Devices · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | InspireMD, Inc. (NSPR) | Chief Commercial Officer | $274,275 | $1,108,199 |
| 2022 | InspireMD, Inc. (NSPR) | Chief Commercial Officer | — | — |
